Skip to content
lifestyle.lincolnlabs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Biomea Fusion, Inc.
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
September 23, 2026
Biomea Fusion Announces Proposed Public Offering of Securities
September 22, 2026
Biomea Fusion to Participate in Upcoming Investor Conferences
September 3, 2026
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
August 24, 2026
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
August 13, 2026
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 5, 2026
Biomea Fusion to Participate at Upcoming Investor Conferences
May 12, 2026
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
May 11, 2026
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
May 5, 2026
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
April 27, 2026
1
2
Next Page
→